On May 24, 2018 Clinical Genomics, a leading provider of colorectal cancer (CRC) testing and solutions, reported that data demonstrating the utility of COLVERA for detection of methylated ctDNA following surgery and prediction of risk for residual and recurrent disease will be presented at 2018 ASCO (Free ASCO Whitepaper) Annual Meeting taking place in Chicago, IL, June 1-5 (Press release, Clinical Genomics, MAY 24, 2018, View Source [SID1234526881]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
COLVERA is a new blood-based test for detection of circulating tumor DNA methylated in the two genes, BCAT1 and IKZF1. The study was performed in collaboration with Flinders Centre for Innovation in Cancer (Adelaide, Australia).
"The observation that the COLVERA blood test, when positive, indicates increased risk of residual disease and subsequently for recurrence has implications for adjuvant therapy and monitoring," stated Dr. Susanne Pedersen, Chief Scientific Officer of Clinical Genomics.
"The results of this study suggest serious consideration for the use of the COLVERA blood test after curative intent surgery and during the post-treatment surveillance period for all Stage II and Stage III CRC patients," added Tadd S. Lazarus, M.D., Chief Medical Officer of Clinical Genomics.
The study selected for poster presentation at this year’s meeting is:
A prospective cohort study in colorectal cancer assessing the relationship between post-surgery detection of methylated BCAT1 or IKZF1 ctDNA and risk for residual disease and survival.
Presenter: David Murray, Senior Scientist, Clinical Genomics
Abstract Number: 3596
Poster Board Number: 89
Data will be presented in Hall A of McCormick Place during Poster Session: Gastrointestinal (Colorectal) Cancer on June 3, 8:00 AM-11:30 AM.